tetano
Editor, Senior Moderator
Sci Rep
. 2021 Aug 30;11(1):17325.
doi: 10.1038/s41598-021-96879-3.
Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
Thomas W McDade[SUP] 1 [/SUP], Alexis R Demonbreun[SUP] 2 [/SUP], Amelia Sancilio[SUP] 3 [/SUP], Brian Mustanski[SUP] 2 [/SUP], Richard T D'Aquila[SUP] 2 [/SUP], Elizabeth M McNally[SUP] 2 [/SUP]
Affiliations
Abstract
Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.
. 2021 Aug 30;11(1):17325.
doi: 10.1038/s41598-021-96879-3.
Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
Thomas W McDade[SUP] 1 [/SUP], Alexis R Demonbreun[SUP] 2 [/SUP], Amelia Sancilio[SUP] 3 [/SUP], Brian Mustanski[SUP] 2 [/SUP], Richard T D'Aquila[SUP] 2 [/SUP], Elizabeth M McNally[SUP] 2 [/SUP]
Affiliations
- PMID: 34462501
- DOI: 10.1038/s41598-021-96879-3
Abstract
Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.